仅供临床科研使用
ILD 了解更多
销售价格： ￥ N/A
商品编号： AS-0386-1473
软件语言： 英文
器械分类： II
生产厂家： Brainomix
公司网址： https://www.brainomix.com/
认证信息： FDA
系统要求： Windows
交付方式： 下载安装
  • 软件概览
  • 推荐配置
  • 典型病例
  • 软件教程
  • 临床文献
  • 用户评价
  • 产品彩页

软件概览

Brainomix 360 e-Lung: Vision to Precision
Brainomix 360 e-Lung is an imaging software that automatically quantifies CT biomarkersin patients with interstitial lung disease (lLD), powered by novel, proprietary technology.
With a recent expansion of its FDA clearance, the next generation e-Lung technology represents a significant stepforward for the care of patients with lLD, with improved Al and machine learning (ML) algorithms, and a longitudinaassessment functionality that enables clinicians to more easily track results across multiple scan timepoints


Robust Validation: INBUlLD Trial
Through a research collaboration with Boehringer Ingelheim, the global leader inpulmonary fibrosis therapies, Brainomix were granted privileged access to the landmarkINBUlLD clinical trial dataset to run the first quantitative CT analysis.
The results firmly validate e-Lung as a reliable tool for identifying progressive pulmonaryfibrosis accurately and sensitively, while also demonstrating its prognostic accuracy inidentifying patients at risk of progressive pulmonary fibrosis.
“The imaging data presented at ATS 2025 from our INBUlLD clinical trial in patients withprogressive pulmonary fibrosis are part of a collaboration with Brainomix and others toadvance the development of imaging biomarkers for better prognostication andprediction of response to therapy and ultimately patient care," Associate Head ofMedicine Therapeutic Area Inflammation at Boehringer Ingelheim.


e-Lung: Advancing Lung Disease Care
Pulmonary fibrosis is a subset of Interstitial Lung Diseases (lLDs), and a chronic lungcondition that is progressive and life-limiting. Untreated, patients can have a lifespan asshort as three to five years from diagnosis, and yet despite this, often wait up to two yearsto be diagnosed.
The key to the best outcome and survival for patients with pulmonary fibrosis is earlyinitiation of treatment. However, identifying patients eligible for treatment based onimaging can be challenging, even for experts.
"e-Lung is a powerful tool, more sensitive to progression than visual analysis and moreaccurate than lung function change. This ability to accurately identify serial change canhelp physicians to make better treatment decisions at an earlier time point. The prognosticcapabilities also allow physicians to prioritize at-risk patients for earlier follow-up, and toescalate their care in a more timely manner," Dr Peter George, Consultant Pulmonologistat the Royal Brompton & Brainomix Medical Director.


Brainomix Al-powered lung imaging biomarkers are available now for use in clinical trials to:     


Hear from our valued partners and collaborators

推荐配置


典型病例


软件教程


临床文献


用户评价

TIPAL StudyNorwich, Uk
"lt is great to have the chance toincorporate the cutting-edge CTscanning technology,e-Lungdeveloped by Brainomix into theTIPAL study.


Elizabeth EstesOSlC Executive Director
"Brainomix's history ofestablishing successfulcollaborations, and theirexpertise in Al imagingbiomarkers, certainly bringspositive momentum to OSlC."

产品彩页


请完善个人信息

非常抱歉，您只有购买软件后才能查看完整软件教程！

看了此商品的会员还在看
测试版
版本号 软件大小 下载地址
01 1m 下载
正式版
版本号 软件大小 下载地址
01 1m 下载